{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:15:54Z","timestamp":1780571754494,"version":"3.54.1"},"reference-count":50,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>Squamous cell carcinoma of the anus and anal canal is a rare malignancy with an increasing incidence in the United States. In the past 2 decades, the proportion of Americans diagnosed with incurable, metastatic anal cancer at the time of initial presentation has increased. Most cases are linked to prior infection with HPV. Although concurrent chemoradiotherapy has been the accepted standard treatment for patients with localized anal cancer over the past half century, therapeutic advances have increased options for patients with unresectable or incurable anal cancer over the past 5 years. Specifically, combination chemotherapy and immunotherapy with anti\u2013PD-(L)1 antibodies has demonstrated efficacy in this setting. Greater understanding of molecular drivers of this viral-associated malignancy has provided critical insight into evolving biomarkers for the clinical management of anal cancer. The pervasiveness of HPV across cases of anal cancer has been leveraged for the development of HPV-specific circulating tumor DNA assays as a sensitive biomarker for prognosticating recurrence in patients with localized anal cancer who complete chemoradiation. For patients with metastatic disease, somatic mutations, well-characterized for anal cancer, have not shown utility in identifying patients who benefit from systemic treatments. Although the overall response rate to immune checkpoint blockade therapies is low for metastatic anal cancer, high immune activation within the tumor and PD-L1 expression may identify patients more likely to experience response. These biomarkers should be incorporated into the design of future clinical trials to personalize further treatment approaches in the evolving management of anal cancer.<\/jats:p>","DOI":"10.6004\/jnccn.2023.7031","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T19:47:37Z","timestamp":1686599257000},"page":"678-684","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic and Predictive Markers for Patients With Anal Cancer"],"prefix":"10.6004","volume":"21","author":[{"given":"Emma B.","family":"Holliday","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Peddireddy","sequence":"additional","affiliation":[{"name":"McGovern Medical School, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van K.","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS,  Cancer statistics, 2023. CA Cancer J Clin 2023;73:17\u201348."},{"key":"B2","series-title":"J Natl Cancer Inst","first-page":"792","article-title":"Incidence trends and burden of human papillomavirus-associated cancers among women in the United States, 2001\u20132017","volume":"113","author":"Deshmukh AA","year":"2021","unstructured":"Deshmukh AA, Suk R, Shiels MS,  Incidence trends and burden of human papillomavirus-associated cancers among women in the United States, 2001\u20132017. J Natl Cancer Inst 2021;113:792\u2013796."},{"key":"B3","series-title":"J Clin Oncol","first-page":"1228","article-title":"State variation in squamous cell carcinoma of the anus incidence and mortality, and association with HIV\/AIDS and smoking in the United States","volume":"41","author":"Damgacioglu H","year":"2023","unstructured":"Damgacioglu H, Lin YY, Ortiz AP,  State variation in squamous cell carcinoma of the anus incidence and mortality, and association with HIV\/AIDS and smoking in the United States. J Clin Oncol 2023;41:1228\u20131238."},{"key":"B4","series-title":"JAMA","first-page":"1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani JA","year":"2008","unstructured":"Ajani JA, Winter KA, Gunderson LL,  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914\u20131921."},{"key":"B5","series-title":"Lancet Oncol","first-page":"516","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James RD","year":"2013","unstructured":"James RD, Glynne-Jones R, Meadows HM,  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial. Lancet Oncol 2013;14:516\u2013524."},{"key":"B6","series-title":"J Clin Oncol","first-page":"1116","article-title":"US intergroup anal carcinoma trial: tumor diameter predicts for colostomy","volume":"27","author":"Ajani JA","year":"2009","unstructured":"Ajani JA, Winter KA, Gunderson LL,  US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol 2009;27:1116\u20131121."},{"key":"B7","series-title":"Lancet Oncol","first-page":"446","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris VK","year":"2017","unstructured":"Morris VK, Salem ME, Nimeiri H,  Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:446\u2013453."},{"key":"B8","series-title":"J Clin Oncol","article-title":"Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): results from the multicohort, phase II KEYNOTE-158 study","volume":"38","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Cassier PA, Fakih M,  Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): results from the multicohort, phase II KEYNOTE-158 study. J Clin Oncol 2020;38(Suppl):Abstract 1."},{"key":"B9","series-title":"ESMO Open","first-page":"100529","article-title":"A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)","volume":"7","author":"Rao S","year":"2022","unstructured":"Rao S, Anandappa G, Capdevila J,  A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open 2022;7:100529."},{"key":"B10","series-title":"J Immunother Cancer","first-page":"e002996","article-title":"Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study","volume":"9","author":"Lonardi S","year":"2021","unstructured":"Lonardi S, Prete AA, Morano F,  Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. J Immunother Cancer 2021;9:e002996."},{"key":"B11","series-title":"Lancet Oncol","first-page":"1094","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study","volume":"19","author":"Kim S","year":"2018","unstructured":"Kim S, Fran\u00e7ois E, Andr\u00e9 T,  Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol 2018;19:1094\u20131106."},{"key":"B12","series-title":"J Clin Oncol","first-page":"2510","article-title":"International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct","volume":"38","author":"Rao S","year":"2020","unstructured":"Rao S, Sclafani F, Eng C,  International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. J Clin Oncol 2020;38:2510\u20132518."},{"key":"B13","series-title":"N Engl J Med","first-page":"1350","article-title":"Sexually transmitted infection as a cause of anal cancer","volume":"337","author":"Frisch M","year":"1997","unstructured":"Frisch M, Glimelius B, van den Brule AJ,  Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997;337:1350\u20131358."},{"key":"B14","series-title":"Oncologist","first-page":"1247","article-title":"Clinicopathologic features associated with human papillomavirus\/p16 in patients with metastatic squamous cell carcinoma of the anal canal","volume":"20","author":"Morris VK","year":"2015","unstructured":"Morris VK, Rashid A, Rodriguez-Bigas M,  Clinicopathologic features associated with human papillomavirus\/p16 in patients with metastatic squamous cell carcinoma of the anal canal. Oncologist 2015;20:1247\u20131252."},{"key":"B15","series-title":"Int J Cancer","first-page":"278","article-title":"Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy","volume":"136","author":"R\u00f6del F","year":"2015","unstructured":"R\u00f6del F, Wieland U, Fraunholz I,  Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Int J Cancer 2015;136:278\u2013288."},{"key":"B16","series-title":"Clin Oncol (R Coll Radiol)","first-page":"e1","article-title":"A systematic review and meta-analysis of prognostic biomarkers in anal squamous cell carcinoma treated with primary chemoradiotherapy","volume":"31","author":"Parwaiz I","year":"2019","unstructured":"Parwaiz I, MacCabe TA, Thomas MG,  A systematic review and meta-analysis of prognostic biomarkers in anal squamous cell carcinoma treated with primary chemoradiotherapy. Clin Oncol (R Coll Radiol) 2019;31:e1\u201313."},{"key":"B17","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"258","article-title":"Human papillomavirus- associated cancers - United States, 2004\u20132008","volume":"61","year":"2012","unstructured":"Centers for Disease Control and Prevention. Human papillomavirus- associated cancers - United States, 2004\u20132008. MMWR Morb Mortal Wkly Rep 2012;61:258\u2013261."},{"key":"B18","series-title":"Transl Oncol","first-page":"101084","article-title":"A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma","volume":"14","author":"Iseas S","year":"2021","unstructured":"Iseas S, Golubicki M, Robbio J,  A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma. Transl Oncol 2021;14:101084."},{"key":"B19","series-title":"Cancers (Basel)","first-page":"2516","article-title":"Evaluation of PD-L1 expression and HPV genotyping in anal squamous cell carcinoma","volume":"12","author":"Wessely A","year":"2020","unstructured":"Wessely A, Heppt MV, Kammerbauer C,  Evaluation of PD-L1 expression and HPV genotyping in anal squamous cell carcinoma. Cancers (Basel) 2020;12:2516."},{"key":"B20","series-title":"Front Oncol","first-page":"1000263","article-title":"The prognostic impact of PD-L1 and CD8 expression in anal cancer patients treated with chemoradiotherapy","volume":"12","author":"Chan AM","year":"2022","unstructured":"Chan AM, Roldan Urgoiti G, Jiang W,  The prognostic impact of PD-L1 and CD8 expression in anal cancer patients treated with chemoradiotherapy. Front Oncol 2022;12:1000263."},{"key":"B21","series-title":"Sci Transl Med","first-page":"346ra92","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie J","year":"2016","unstructured":"Tie J, Wang Y, Tomasetti C,  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8:346ra92."},{"key":"B22","series-title":"Clin Cancer Res","first-page":"5857","article-title":"HPV sequencing facilitates ultrasensitive detection of HPV circulating tumor DNA","volume":"27","author":"Leung E","year":"2021","unstructured":"Leung E, Han K, Zou J,  HPV sequencing facilitates ultrasensitive detection of HPV circulating tumor DNA. Clin Cancer Res 2021;27:5857\u20135868."},{"key":"B23","series-title":"Clin Cancer Res","first-page":"5767","article-title":"Prognostic impact of residual HPV ctDNA detection after chemoradiotherapy for anal squamous cell carcinoma","volume":"24","author":"Cabel L","year":"2018","unstructured":"Cabel L, Jeannot E, Bieche I,  Prognostic impact of residual HPV ctDNA detection after chemoradiotherapy for anal squamous cell carcinoma. Clin Cancer Res 2018;24:5767\u20135771."},{"key":"B24","series-title":"J Hepatocell Carcinoma","first-page":"57","article-title":"Radiation-associated lymphopenia and outcomes of patients with unresectable hepatocellular carcinoma treated with radiotherapy","volume":"8","author":"De B","year":"2021","unstructured":"De B, Ng SP, Liu AY,  Radiation-associated lymphopenia and outcomes of patients with unresectable hepatocellular carcinoma treated with radiotherapy. J Hepatocell Carcinoma 2021;8:57\u201369."},{"key":"B25","series-title":"Int J Radiat Oncol Biol Phys","first-page":"128","article-title":"Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy","volume":"99","author":"Davuluri R","year":"2017","unstructured":"Davuluri R, Jiang W, Fang P,  Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy. Int J Radiat Oncol Biol Phys 2017;99:128\u2013135."},{"key":"B26","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1451","article-title":"Lymphocyte migration and radiation lymphopenia","volume":"7","author":"Ekstrand KE","year":"1981","unstructured":"Ekstrand KE, Plunkett S, Heise ER,  Lymphocyte migration and radiation lymphopenia. Int J Radiat Oncol Biol Phys 1981;7:1451\u20131455."},{"key":"B27","series-title":"Laryngoscope","first-page":"121","article-title":"Infiltrating lymphocytes and human papillomavirus-16\u2013associated oropharyngeal cancer","volume":"122","author":"Wansom D","year":"2012","unstructured":"Wansom D, Light E, Thomas D,  Infiltrating lymphocytes and human papillomavirus-16\u2013associated oropharyngeal cancer. Laryngoscope 2012;122:121\u2013127."},{"key":"B28","series-title":"Oncologist","first-page":"1015","article-title":"Chemoradiation-related lymphopenia and its association with survival in patients with squamous cell carcinoma of the anal canal","volume":"25","author":"Lee G","year":"2020","unstructured":"Lee G, Kim DW, Muralidhar V,  Chemoradiation-related lymphopenia and its association with survival in patients with squamous cell carcinoma of the anal canal. Oncologist 2020;25:1015\u20131022."},{"key":"B29","series-title":"J Gastrointest Oncol","first-page":"2412","article-title":"Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma","volume":"12","author":"De B","year":"2021","unstructured":"De B, Ludmir EB, Messick CA,  Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma. J Gastrointest Oncol 2021;12:2412\u20132422."},{"key":"B30","series-title":"Ann Oncol","first-page":"1336","article-title":"Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes","volume":"27","author":"Chung JH","year":"2016","unstructured":"Chung JH, Sanford E, Johnson A,  Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. Ann Oncol 2016;27:1336\u20131341."},{"key":"B31","series-title":"Mol Cancer Res","first-page":"1542","article-title":"Comprehensive genomic profiling of metastatic squamous cell carcinoma of the anal canal","volume":"15","author":"Morris V","year":"2017","unstructured":"Morris V, Rao X, Pickering C,  Comprehensive genomic profiling of metastatic squamous cell carcinoma of the anal canal. Mol Cancer Res 2017;15:1542\u20131550."},{"key":"B32","series-title":"Oncotarget","first-page":"464","article-title":"Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma","volume":"9","author":"Cacheux W","year":"2017","unstructured":"Cacheux W, Dangles-Marie V, Rouleau E,  Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. Oncotarget 2017;9:464\u2013476."},{"key":"B33","series-title":"Mol Cancer","first-page":"26","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang J","year":"2019","unstructured":"Yang J, Nie J, Ma X,  Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer 2019;18:26."},{"key":"B34","series-title":"J Gastrointest Oncol","first-page":"2423","article-title":"Molecular characterization of squamous cell carcinoma of the anal canal","volume":"12","author":"Armstrong SA","year":"2021","unstructured":"Armstrong SA, Malley R, Wang H,  Molecular characterization of squamous cell carcinoma of the anal canal. J Gastrointest Oncol 2021;12:2423\u20132437."},{"key":"B35","series-title":"Cell","first-page":"1129","article-title":"The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53","volume":"63","author":"Scheffner M","year":"1990","unstructured":"Scheffner M, Werness BA, Huibregtse JM,  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129\u20131136."},{"key":"B36","series-title":"Mol Cell Biol","first-page":"9094","article-title":"Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo","volume":"23","author":"Balsitis SJ","year":"2003","unstructured":"Balsitis SJ, Sage J, Duensing S,  Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol Cell Biol 2003;23:9094\u20139103."},{"key":"B37","series-title":"Nature","first-page":"330","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330\u2013337."},{"key":"B38","series-title":"N Engl J Med","first-page":"1632","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz S","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R,  Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 2019;381:1632\u20131643."},{"key":"B39","series-title":"N Engl J Med","first-page":"1757","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis CS","year":"2008","unstructured":"Karapetis CS, Khambata-Ford S, Jonker DJ,  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757\u20131765."},{"key":"B40","series-title":"J Clin Oncol","first-page":"1626","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado RG","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M,  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626\u20131634."},{"key":"B41","series-title":"Expert Rev Anticancer Ther","first-page":"901","article-title":"Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma","volume":"20","author":"Rogers JE","year":"2020","unstructured":"Rogers JE, J\u00e1come AA, Ohinata A,  Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. Expert Rev Anticancer Ther 2020;20:901\u2013908."},{"key":"B42","series-title":"Clin Colorectal Cancer","first-page":"e39","article-title":"FOLFCIS treatment and genomic correlates of response in advanced anal squamous cell cancer","volume":"18","author":"Mondaca S","year":"2019","unstructured":"Mondaca S, Chatila WK, Bates D,  FOLFCIS treatment and genomic correlates of response in advanced anal squamous cell cancer. Clin Colorectal Cancer 2019;18:e39\u201352."},{"key":"B43","series-title":"Ann Oncol","first-page":"S412","article-title":"Atezolizumab in combination with bevacizumab for patients with unresectable\/metastatic anal cancer","volume":"31","author":"Morris V","year":"2020","unstructured":"Morris V, Liu S, Johnson B,  Atezolizumab in combination with bevacizumab for patients with unresectable\/metastatic anal cancer. Ann Oncol 2020;31(Suppl_4):S412."},{"key":"B44","series-title":"Immunotherapy","first-page":"1481","article-title":"The efficacy of PD-1\/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients","volume":"11","author":"Chen RL","year":"2019","unstructured":"Chen RL, Zhou JX, Cao Y,  The efficacy of PD-1\/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients. Immunotherapy 2019;11:1481\u20131490."},{"key":"B45","series-title":"Lancet","first-page":"759","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun JM","year":"2021","unstructured":"Sun JM, Shen L, Shah MA,  Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021;398:759\u2013771."},{"key":"B46","series-title":"Ann Oncol","first-page":"1032","article-title":"Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)","volume":"25","author":"Goldstein J","year":"2014","unstructured":"Goldstein J, Tran B, Ensor J,  Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 2014;25:1032\u20131038."},{"key":"B47","series-title":"Science","first-page":"409","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le DT","year":"2017","unstructured":"Le DT, Durham JN, Smith KN,  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409\u2013413."},{"key":"B48","series-title":"Lancet Oncol","first-page":"1353","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J,  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353\u20131365."},{"key":"B49","series-title":"J Immunother Cancer","first-page":"e001395","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus-associated malignancies","volume":"8","author":"Strauss J","year":"2020","unstructured":"Strauss J, Gatti-Mays ME, Cho BC,  Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus-associated malignancies. J Immunother Cancer 2020;8:e001395."},{"key":"B50","series-title":"N Engl J Med","first-page":"24","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi HA","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ,  Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022;386:24\u201334."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/6\/article-p678.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/6\/article-p678.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/6\/article-p678.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T19:47:38Z","timestamp":1686599258000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/6\/article-p678.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":50,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.7031","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}